Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + docetaxel + carboplatin
- Development stage
- Phase 2
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of sorafenib (a multi-kinase inhibitor), docetaxel (a cytotoxic chemotherapy agent), and carboplatin (an alkylating agent). The combination has been studied in clinical trials for various cancers. Sorafenib inhibits multiple intracellular and cell surface kinases involved in tumor cell signaling, proliferation, angiogenesis, and apoptosis, including Raf kinases, VEGFR, PDGFR-β, KIT, and FLT-3. Docetaxel and carboplatin are cytotoxic chemotherapy agents commonly used in cancer treatment.
02
Targets
BRAF V600ERAF1 (c-Raf-1 (Y340D/Y341D))DNAFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sorafenib + docetaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + docetaxel + carboplatin.